Tech Transfer Roundup: Be Cool Therapeutics Sees Potential In Mimicking Hibernation
Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.
You may also be interested in...
MYR’s Hepcludex obtained EU accelerated approval in July, making it the first approved therapy for hepatitis D. One analyst sees the drug as a blockbuster revenue opportunity for Gilead.
Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.
U.K.-based academic research teams will be able to apply to work with the AstraZeneca compounds free of charge and receive grant funding from MRC under the collaboration.